SMS Pharmaceuticals Limited — Others, 30-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

SMS Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. The company confirmed disciplined capital use, with no deviation in the utilisation of funds raised through the preferential issue of 90 lakh warrants. Out of these, 40 lakh warrants were fully converted into equity shares, reinforcing confidence in its funding approach and growth strategy, which is positive for shareholders.